Medicus Pharma MDCX 深 滬
等待開盤 11-07 09:30:00 美东时间
1.87
+0.040
+2.19%
華盛通- 最 高2.00
- 今 開1.88
- 成交量 3.02万股
- 最 低 1.81
- 昨 收 1.83
- 總市值 355.18万
- 52周最高 127.50
- 市盈率 靜 --
- 換手率 1.59%
- 52周最低 1.70
- 委 比 -98.41%
- 總股本 189.93万
- 歷史最高 447.00
- 量 比 0.36
- 振 幅 10.38%
- 歷史最低 1.70
- 每 手 1
- 風險率 33.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Medicus Prioritizes CD228V as Q3 Loss Narrows
Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus designated C...
今天 06:12
Medicus Pharma Q3 EPS $(11.64) Misses $(6.63) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(11.64) per share which missed the analyst consensus estimate of $(6.63) by 75.83 percent. This is a 79.21 percent increase over losses of $(56.00) per share from the same period last year.
今天 05:31
Medicus Pharma to Present at BIO-Europe 2026
Medicus Pharma Ltd. will present at BIO-Europe 2026 in Cologne, Germany, on November 9-11, 2026. Dr. Faisal Mehmud, the company's Chief Medical Officer, will discuss its precision oncology focus, including CD228V, an antibody-drug conjugate targeting melanoma and other cancers, and SkinJect®, a localized immuno-oncology product for basal cell carcinoma in Gorlin syndrome patients. The presentation will also cover the Teverelix® program. The event...
11-05 12:30
Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing
Medicus Pharma Ltd. subsidiary SkinJect, Inc. has entered into a non-binding letter of intent with a SPAC for a proposed $135 million business combination to establish a dedicated platform for its rare-disease dermatology program in Gorlin syndrome. The transaction would allow Medicus to retain majority ownership while securing financing for the SKNJCT-005 NDA-enabling study. SkinJect’s investigational microneedle patch delivers doxorubicin for b...
11-04 13:30
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
Medicus Pharma Ltd. announced that its CEO, Dr. Raza Bokhari, will speak at BioFuture 2026 in NYC and deliver a keynote at Global Biotechnology Summit 2026 in Abu Dhabi. The presentations will focus on the company's progress in targeted cancer therapeutics, including CD228V, an antibody-drug conjugate, and SkinJect®, an investigational localized immuno-oncology product for Gorlin syndrome patients. The company is advancing these assets while seek...
10-27 11:30
Medicus Pharma Regains Compliance with Nasdaq Listing Rules
The latest announcement is out from Medicus Pharma Ltd ( ($MDCX) ). On October ...
10-24 05:52
Medicus Pharma Announces Nasdaq-Compliant Share Consolidation
Medicus Pharma Ltd ( ($MDCX) ) has issued an update. Medicus Pharma Ltd. implem...
10-17 05:18
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why
Medicus Pharma Ltd. (NASDAQ:MDCX) shares fell 24.22% to $0.12 in after-hours trading Wednesday after the company announced a 50-to-1 consolidation of its common shares. Medicus Pharma is a biopharmaceutical company. The Share Consolidation The consolidation will take effect Oct. 12, with every 50 co...
10-08 15:28
Medicus Pharma announces major share consolidation plan
Medicus Pharma Ltd ( ($MDCX) ) has provided an update. Medicus Pharma Ltd. will...
10-08 04:31
Medicus Pharma shares are trading lower after the company announced a 50-for-1 stock split.
Medicus Pharma shares are trading lower after the company announced a 50-for-1 stock split.
10-08 04:24
